Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $30.68, for a total value of $460,200.00. Following the completion of the sale, the chief executive officer directly owned 671,907 shares of the company’s stock, valued at $20,614,106.76. This represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cameron Turtle also recently made the following trade(s):

• On Monday, December 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $29.02, for a total value of $435,300.00.
• On Monday, November 3rd, Cameron Turtle sold 45,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $23.33, for a total value of $1,049,850.00.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock opened at $31.05 on Thursday. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $35.31. The stock’s 50-day simple moving average is $29.13 and its 200 day simple moving average is $21.39. The stock has a market capitalization of $2.41 billion, a P/E ratio of -14.18 and a beta of 3.17.

Spyre Therapeutics (NASDAQ:SYRE) last issued its earnings results on Tuesday, November 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.53. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft initiated coverage on Spyre Therapeutics in a research note on Friday, September 26th. They set a “buy” rating and a $43.00 price objective on the stock. Wall Street Zen upgraded Spyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Mizuho upgraded Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Citigroup assumed coverage on shares of Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $53.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC raised its stake in Spyre Therapeutics by 357.8% in the second quarter. CWM LLC now owns 1,712 shares of the company’s stock valued at $26,000 after purchasing an additional 1,338 shares in the last quarter. AlphaQuest LLC raised its position in shares of Spyre Therapeutics by 30.8% during the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock valued at $62,000 after buying an additional 983 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Spyre Therapeutics by 2,881.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after buying an additional 4,092 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Spyre Therapeutics by 25.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,091 shares of the company’s stock worth $76,000 after acquiring an additional 1,045 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Spyre Therapeutics by 182.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after acquiring an additional 3,725 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.